Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Kalvista Pharmaceuticals Inc
(NQ:
KALV
)
9.460
-0.270 (-2.77%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kalvista Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
Next >
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
July 07, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology
June 12, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Analyst Expectations for KalVista Pharma's Future
April 21, 2023
Via
Benzinga
KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
June 02, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference
May 31, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference
May 23, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
May 08, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop
April 27, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
March 09, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 27, 2023
Via
Benzinga
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
February 27, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology
February 16, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development
February 14, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet
February 10, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session
February 07, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
February 03, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President
January 05, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Gold Rises Over 1%; Elys Game Technology Shares Spike Higher
December 27, 2022
U.S. stocks traded mixed toward the end of trading, with the Dow Jones trading slightly higher on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 27, 2022
Via
Benzinga
Major Indexes Falter As Rocky Year Wraps Up
December 27, 2022
Stocks are struggling to build on their morning gains as investors began to waver on the possibility of a
Via
Talk Markets
Dow Rises 100 Points; Crude Oil Rises Over 1%
December 27, 2022
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Tuesday.
Via
Benzinga
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session
December 27, 2022
Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Technology and Cloakbook DC have been granted license to open sportsbook in Washington, D.C.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 27, 2022
Via
Benzinga
KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering
December 27, 2022
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.